Patrick Daly

DocwireNews

In a study, published in the&nbsp;European Journal of Clinical Pharmacology, researchers investigated whether Janus kinase (JAK) inhibitors were associated with increased risk of venous thromboembolic (VTE) and arterial thromboembolic (ATE) events. According to the study&rsquo;s lead author, Amandine Gouverneur, the researchers&rsquo; findings suggested that baricitinib and tofacitinib were associated with an increased risk of VTE and ATE.The self-controlled case series study utilized data from 5870 patients within the French healthcare insurance system database SNDS who were dispensed <a href="https://medlineplus.gov/druginfo/meds/a618033.html" target="_blank" rel="noopener">baricitinib</a> or <a href="https://medlineplus.gov/druginfo/meds/a613025.html" target="_blank" rel="noopener">tofacitinib</a> and experienced at least one VTE or ATE event between November 2017 and June 2019. Researchers used incident rate ratios (IRR) to identify potential associations between JAK inhibitor treatment and <a href="https://www.docwirenews.com/cardiology/validating-assessment-models-for-predicting-risk-of-venous-thromboembolism/">thromboembolic events</a> within 30 or 60 days.<h2>JAK Inhibitors Appear to Associate With VTE and ATE Events</h2>Reportedly, among the cohort, 92 patients had incident VTE or ATE within the post-exposure periods. These patients had a median age at JAK inhibitor initiation of 65.7 years (interquartile range [IQR], 56.1-75.8), and were 65.2% female (n=60). A total of 60 patients received baricitinib, 30 received tofacitinib, and 2 received both.VTE and ATE events occured in 38 (41.3%) and 54 (58.7%) patients, respectively, with a median time-to-event after initiating JAK inhibition of 4.6 months (IQR, 2.5-9.2) for VTE and 6.1 months (IQR, 3.0-8.5) for ATE. The IRR for VTE during JAK inhibitor treatment was 8.27 (95% CI, 3.41-20.04), and the authors noted the risk remained elevated during the 30-day post-exposure period (6.52; 95% CI, 2.02-21.11).Likewise, ATE had an IRR of 9.27 (95% CI, 3.68-23.34) which also remained increased during the 30-day post-exposure period (10.12; 95% CI, 3.27-31.37). The authors did add that no risk increase was identified during long-term post-exposure for ATE or VTE.Overall, the researchers concluded that their study &ldquo;shows evidence of an increased risk of VTE and ATE associated with the use of baricitinib and tofacitinib.&rdquo;Browse More <a href="https://www.docwirenews.com/venous-thromboembolism-knowledge-hub/">Related Research on the Venous Thromboembolism Knowledge Hub</a>

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

Janus Kinase Inhibitors Associated With Thromboembolic Events

In a study, published in the European Journal of Clinical Pharmacology, researchers investigated whether Janus kinase (JAK) inhibitors were associated with increased risk of ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe